Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

1.

Advances in prostate cancer chemoprevention: a translational perspective.

Nambiar D, Singh RP.

Nutr Cancer. 2013;65 Suppl 1:12-25. doi: 10.1080/01635581.2013.785006. Review.

PMID:
23682779
2.

Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.

Mateen S, Raina K, Agarwal R.

Nutr Cancer. 2013;65 Suppl 1:3-11. doi: 10.1080/01635581.2013.785004. Review.

3.

Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B.

Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, Zhang HY, Li YW.

Eur J Clin Microbiol Infect Dis. 2013 May;32(5):657-69. doi: 10.1007/s10096-012-1789-1. Epub 2012 Dec 18. Review.

PMID:
23247631
4.

Hepatitis C virus and natural compounds: a new antiviral approach?

Calland N, Dubuisson J, Rouillé Y, Séron K.

Viruses. 2012 Oct 17;4(10):2197-217. doi: 10.3390/v4102197. Review.

5.

Hepatitis C viral kinetics: the past, present, and future.

Chatterjee A, Smith PF, Perelson AS.

Clin Liver Dis. 2013 Feb;17(1):13-26. doi: 10.1016/j.cld.2012.09.003. Review.

6.

Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease.

Hackett ES, Twedt DC, Gustafson DL.

J Vet Intern Med. 2013 Jan-Feb;27(1):10-6. doi: 10.1111/jvim.12002. Epub 2012 Nov 9. Review.

PMID:
23140176
7.

Silymarin for HCV infection.

Polyak SJ, Oberlies NH, Pécheur EI, Dahari H, Ferenci P, Pawlotsky JM.

Antivir Ther. 2013;18(2):141-7. doi: 10.3851/IMP2402. Epub 2012 Sep 25. Review.

8.

Hepatitis C therapy in non-genotype 1 patients: the near future.

Wartelle-Bladou C, Le Folgoc G, Bourlière M, Lecomte L.

J Viral Hepat. 2012 Aug;19(8):525-36. doi: 10.1111/j.1365-2893.2012.01634.x. Review.

PMID:
22762136
9.

Complementary and alternative medicines in prostate cancer: from bench to bedside?

Klempner SJ, Bubley G.

Oncologist. 2012;17(6):830-7. doi: 10.1634/theoncologist.2012-0094. Epub 2012 May 22. Review.

10.

Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature.

Dashti-Khavidaki S, Shahbazi F, Khalili H, Lessan-Pezeshki M.

J Pharm Pharm Sci. 2012;15(1):112-23. Review.

11.

Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning.

Mengs U, Pohl RT, Mitchell T.

Curr Pharm Biotechnol. 2012 Aug;13(10):1964-70. Review.

12.

Immunosuppression, liver injury and post-transplant HCV recurrence.

Ciesek S, Wedemeyer H.

J Viral Hepat. 2012 Jan;19(1):1-8. doi: 10.1111/j.1365-2893.2011.01548.x. Epub 2011 Nov 7. Review.

PMID:
22187942
13.

Reassessing bioavailability of silymarin.

Javed S, Kohli K, Ali M.

Altern Med Rev. 2011 Sep;16(3):239-49. Review.

14.

Silybin and the liver: from basic research to clinical practice.

Loguercio C, Festi D.

World J Gastroenterol. 2011 May 14;17(18):2288-301. doi: 10.3748/wjg.v17.i18.2288. Review.

15.

Silymarin in the prevention and treatment of liver diseases and primary liver cancer.

Féher J, Lengyel G.

Curr Pharm Biotechnol. 2012 Jan;13(1):210-7. Review.

PMID:
21466434
16.

Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer.

Shanmugam MK, Kannaiyan R, Sethi G.

Nutr Cancer. 2011;63(2):161-73. doi: 10.1080/01635581.2011.523502. Review.

PMID:
21294053
17.

Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.

Deep G, Agarwal R.

Cancer Metastasis Rev. 2010 Sep;29(3):447-63. doi: 10.1007/s10555-010-9237-0. Review.

18.

Milk thistle in liver diseases: past, present, future.

Abenavoli L, Capasso R, Milic N, Capasso F.

Phytother Res. 2010 Oct;24(10):1423-32. doi: 10.1002/ptr.3207. Review.

PMID:
20564545
20.

Patented bioavailability enhancement techniques of silymarin.

Javed S, Kohli K, Ali M.

Recent Pat Drug Deliv Formul. 2010 Jun;4(2):145-52. Review.

PMID:
20156178
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk